October 23, 2016 5:43 PM ET


Company Overview of Sagent Pharmaceuticals, Inc.

Company Overview

Sagent Pharmaceuticals, Inc. develops, sources, manufactures, and markets injectable pharmaceuticals in North America. The company offers anti-infective products, such as Cefepime, an antibiotic used to treat infections of the urinary tract, and skin and skin structures, as well as moderate to severe pneumonia, intra-abdominal infections, and as empiric therapy for febrile neutropenic patients; and Levofloxacin, a fluoroquinolone antibacterial for the treatment of infections caused by susceptible bacteria, including nosocomial and community acquired pneumonia, sinusitis, chronic bronchitis, skin and skin structure infections, prostatitis, urinary tract infection, and pyelonephritis in adults...

1901 North Roselle Road

Suite 700

Schaumburg, IL 60195

United States

Founded in 2006

440 Employees





Key Executives for Sagent Pharmaceuticals, Inc.

Chief Executive Officer and Director
Age: 58
Chief Financial Officer and Executive Vice President
Age: 52
Executive Vice President of Global Operations
Age: 61
Principal Accounting Officer, Vice President and Controller
Age: 41
Executive Vice President of Business Development
Age: 44
Compensation as of Fiscal Year 2016.

Sagent Pharmaceuticals, Inc. Key Developments

Sagent Pharmaceuticals Files Form 15

Sagent Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock, $ 0.01 par value per share under the Securities Exchange Act of 1934, as amended.

Sagent Pharmaceuticals, Inc.(NasdaqGM:SGNT) dropped from NASDAQ Biotechnology Index

Sagent Pharmaceuticals, Inc. has been removed from NASDAQ Biotech Index.

Sagent Pharmaceuticals, Inc. Announces Cessation of Board of Directors

Sagent Pharmaceuticals, Inc. announced that at the Effective Time the directors of Purchaser immediately prior to the Effective Time became the directors of the Company until the earlier of their resignation or removal or until their respective successors are duly designated, as the case may be, and each of Robert Flanagan, Anthony Krizman, Mary Taylor Behrens, Michael Fekete and Shlomo Yanai ceased serving as directors of the Company.

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

July 27, 2016
Teva Pharmaceutical Industries Limited, Rights and Assets Related to 79 Pharmaceutical Products
July 11, 2016
February 9, 2016
Sagent (China) Pharmaceuticals Co. Ltd.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sagent Pharmaceuticals, Inc., please visit www.sagentpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.